# A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution

> **NCT00680108** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 62 (estimated)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** diquafosol tetrasodium (INS365) ophthalmic solution

## Key facts

- **NCT ID:** NCT00680108
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2000-05
- **Final completion:** 2000-05
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2015-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680108, "A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00680108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*